Refine your strategic understanding of the BioSecure Act through the latest installment in the "BioSecure Insights" series. This supplementary document enhances our "Policy Brief: Navigating the BioSecure Act: A Multidimensional Analysis," offering a meticulous critique of the Congressional Budget Office’s (CBO) “Cost Estimates” published on April 17, 2024. Our analysis employs several analytical approaches, including the use of a sample from a government contract dataset, which underscores the potential of the Act to catalyze market disruptions and curtail crucial research and development (R&D) initiatives, indicating significant repercussions across governmental, societal, and commercial landscapes. Our review raises concerns that the CBO’s projections might underrepresent the fiscal burdens, suggesting a possible escalation in governmental expenditure. We advocate for a more holistic appraisal to thoroughly comprehend both the economic and societal ramifications, emphasizing the indispensable benefits of sustained R&D efforts. Drawing on historical precedents, such as the impacts of the Affordable Care Act, we champion the adoption of more refined forecasting methods and provide other recommendations.